Synuclein Therapeutic Acceleration Program (SynTAP 2013)


MJFF has made significant investments in research to understand alpha-synuclein and to translate it into therapeutic strategies for advancing a cure for Parkinson’s disease. Through the SynTAP 2013 program, MJFF seeks to aggressively move therapeutic compounds and biologics targeting alpha-synuclein into clinical testing. MJFF seeks proposals for obtaining additional preclinical efficacy data, confirmation of target engagement, evaluation of pharmacokinetics/pharmacodynamics (PK/PD), dose-formulation, safety pharmacology and toxicology studies, which would provide supporting data to enable first-in-human (IND-enabling) studies.

Termini IISPV

Cal comunicar abans del 4 de març de 2013 que es vol participar a la convocatòria, enviant un e-mail a . Termini: 25 de març de 2013

Termini Oficial

Informational Conference Call*: March 13, 2013, 12:00 pm (EST)
Pre-Proposals Due: April 3, 2013
Full Proposal Invitations: April 24, 2013
Full Proposals Due: June 12, 2013
Anticipated Award Announcement: September 2013
Anticipated Funding: October 2013

*MJFF will hold a 45-minute conference call at the time listed above to clarify and explain the goals of this funding initiative and answer applicant questions. To participate in the call and receive call-in details, please RSVP via email to

Estàs interessat?

Omple el següent formulari per rebre més informació: